The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Shanghai Jiao Tong University

Status and phase: Not yet enrolling; Early Phase 1

Conditions: Acute Leukemia

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT06876701

CSPC-DED-AML-KXX

Details and patient eligibility

About

Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
2. Age: 18-75 years old (including boundary values of 18 and 75);
3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity

Exclusion criteria

The subject's previous history of anti-tumor treatment meets one of the following conditions:

1. Individuals who have previously received bevacizumab
2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Experimental group

Experimental group

Treatment:

Drug: Bevacizumab